Posts by author
Janet Fricker
Antimicrobial exposure linked to poorer survival in triple negative breast cancer
Each additional total or unique monthly antimicrobial prescription is associated with inferior overall and breast-cancer-specific survival in women with triple negative breast cancer (TNBC). The study published in Nature Communications, 12 April 2023, found that the association was directly related…
Trial platform informs precision treatment of childhood cancers
A stratified medicine basket study has shown the benefit of combining two targeted therapies to treat paediatric cancers with specific molecular profiles. The study, presentation number CT019, presented at the AACR (American Association for Cancer Research) Annual Meeting 2023, held…
Personalised RNA vaccine combined with immune checkpoint inhibitor shows efficacy in melanoma
In advanced melanoma, adding a personalised mRNA-based vaccine to the immune checkpoint inhibitor pembrolizumab improved recurrence-free survival compared with pembrolizumab alone. The KEYNOTE-942 study (presentation number CT001), presented at the AACR (American Association for Cancer Research) Annual Meeting 2023, held…
Intermittent dosing of exemestane is non-inferior to daily dosing
Giving the aromatase inhibitor (AI) exemestane 25 mg three times weekly was non-inferior to the standard dosing of 25mg daily among study participants who complied with the schedule. The international, multicentric study, which was supported by the US National Cancer…
Body weight influences breast cancer risk in women with BRCA1 and 2 mutations
Obesity may be a factor contributing to DNA damage in the breast tissue of women with BRCA1 or BRCA2 mutations. The study, published in Science Translational Medicine, February 22, suggests maintaining a healthy body weight or pharmacologically targeting oestrogen or…
Improving outcomes in elderly patients taking multiple medications
For older patients with cancer, taking multiple medications can result in toxic chemotherapy side effects and even the need to stop cancer treatment. The cohort study, published in Cancer, 24th January, found cancer patients with one or more potential drug…
Localised prostate cancer: active monitoring offers valid option
Active monitoring of localised prostate cancer has the same high rates of survival after 15 years as radiotherapy or surgery. The ProtecT trial, presented at the European Association of Urology (EAU) meeting in Milan, March 10–13, and published simultaneously in…
Immunotherapy: three studies point to potential strategies to improve response
Over the past 10 years, immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape of cancer, becoming standard treatments for metastatic melanoma, renal cell carcinoma, head and neck cancer, and non-small cell lung cancers (NSCLC). “ICIs have revolutionised care in…
Radiotherapy can be safely omitted in older women with low-risk breast cancer
Leaving out radiotherapy does not affect survival after breast-conserving surgery in older women with low-risk hormone-receptor-positive early breast cancer. Ten-year outcomes for the PRIME II trial, published in the New England Journal of Medicine, February 16, found that, although omission…
Plant-based diets cut risk of prostate cancer progression and recurrence by over 50%
Prostate cancer patients who consume the highest intakes of plant-based foods lower their risk of progression and recurrence. The study, abstract 392 presented at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium, held in San Francisco, February…